SCHEMBL1668615

SCHEMBL1668615

CS(=O)(=O)N1CC=C(c2cc(F)c(OC3CN(Cc4ccc(C(F)(F)F)cc4)C3)c(F)c2)CC1

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CCNT1 O60563 7/20 0.41
CDK9 P50750 7/20 0.41
GPR119 Q8TDV5 5/20 0.38
KCNH2 Q12809 3/20 0.38
EGLN1 Q9GZT9 1/20 0.37
CYP2D6 P10635 1/20 0.35
TACR1 P25103 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1668916 0.83 TRPV1 (0.39)
SCHEMBL1668235 0.81 KDM4E (0.53) KDM4EALDH1A1GPR119KCNH2CYP2D6
SCHEMBL12198376 0.80 KDM4E (0.40) KDM4EALDH1A1TACR1
SCHEMBL1668410 0.80 KDM4E (0.49) KDM4EALDH1A1GPR119KCNH2CYP2D6
SCHEMBL1668310 0.77 KDM4E (0.46) KDM4EALDH1A1GPR119KCNH2CYP2D6
SCHEMBL1668262 0.75 KDM4E (0.48) KDM4EALDH1A1GPR119KCNH2CYP2D6
SCHEMBL12198321 0.73 KDM4E (0.52) KDM4EALDH1A1GPR119KCNH2CYP2D6
SCHEMBL1671394 0.73 EPHX2 (0.46) KDM4EALDH1A1GPR119KCNH2EGLN1
SCHEMBL1668617 0.72 KDM4E (0.41) KDM4EALDH1A1GPR119KCNH2
SCHEMBL1668529 0.72 KDM4E (0.51) KDM4EALDH1A1GPR119KCNH2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US claimed
EP-2486033-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2012-08-15 EP claimed
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-10-06 US claimed
WO-2011044001-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-04-14 WO claimed
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US disclosed
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US disclosed
EP-2486033-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2012-08-15 EP disclosed
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-10-06 US disclosed
WO-2011044001-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY GPR119, GPR65, GPR39 KDM4E 3454/4885ALDH1A1 2341/4885CCNT1 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.